Percheron Therapeutics Ltd

$0.003

Day Range

$0.003 – $0.003

52 Week Range

$0.003 – $0.012

Volume

5.07M

Avg Volume (10D)

3.54M

Market Cap

$4.57M

Price Chart

Market Statistics

Open$0.003

Previous Close$0.003

Day High$0.003

Day Low$0.003

52 Week High$0.012

52 Week Low$0.003

Valuation

Market Cap4.57M

Shares Outstanding1.52B

Price to Book0.48

Trading Activity

Volume5.07M

Value Traded15.20K

Bid$0.002 × 35,031,630

Ask$0.003 × 500,056

Performance

1 Day-25.00%

5 Day-14.29%

13 Week-25.00%

52 Week-62.94%

YTD-65.00%

Technical Indicators

RSI (14)42.87

50-Day SMA$0.004

200-Day SMA$0.006

Percheron Therapeutics acquires worldwide licence to commercialise HMBD-002 cancer therapy

Percheron Therapeutics (ASX: PER) has acquired a worldwide exclusive license from Singapore-based Hummingbird Bioscience for monoclonal antibody therapy HMBD-002 to treat a range of cancer indications. The company will pay Hummingbird an upfront consideration of $4.6 million plus milestone payments of as much as $443m and royalties on net sales of the commercial product. Percheron […]

By Imelda Cotton··1 min read min read

Biotechnology

Percheron Therapeutics completes toxicology study for avicursen ahead of US FDA discussions

Australian biotechnology company Percheron Therapeutics (ASX: PER) has completed a nine-month toxicology study in non-human primates for its lead program, avicursen. Avicursen is an antisense oligonucleotide that targets the CD49d biomarker. The study, which commenced in March 2023, concluded its final dosing on schedule in December. Recovery phase The majority of subjects in the study […]

By Imelda Cotton··1 min read min read